The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer
Open accessAbstract
UNLABELLED: Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate cancer (PCa) cells, particularly in androgen-independent, advanced, and metastatic disease. Previously, we demonstrated that N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) could image an experimental model of PSMA-positive PCa using PET. Here, we describe the initial clinical experience and radiation dosimetry of (18)F-DCFBC in men with metastatic PCa. METHODS: Five patients with radiologic evidence of metastatic PCa were studied after the intravenous administration of 370 MBq (10 mCi) of (18)F-DCFBC. Serial PET was performed until 2 h after administration. Time-activity curves were generated for selected normal tissues and metastatic foci. Radiation dose estimates were calculated using OLINDA/EXM 1.1. RESULTS: Most vascular organs demonstrated a slow decrease in radioactivity concentration over time consistent with clearance from the blood pool, with primarily urinary radiotracer excretion. Thirty-two PET-positive suspected metastatic sites were identified, with 21 concordant on both PET and conventional imaging for abnormal findings compatible with metastatic disease. Of the 11 PET-positive sites not identified on conventional imaging, most were within the bone and could be considered suggestive for the detection of early bone metastases, although further validation is needed. The highest mean absorbed dose per unit administered radioactivity (μGy/MBq) was in the bladder wall (32.4), and the resultant effective dose was 19.9 ± 1.34 μSv/MBq (mean ± SD). CONCLUSION: Although further studies are needed for validation, our findings demonstrate the potential of (18)F-DCFBC as a new positron-emitting imaging agent for the detection of metastatic PCa. This study also provides dose estimates for (18)F-DCFBC that are comparable to those of other PET radiopharmaceuticals such as (18)F-FDG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Tissue Substitutes in Radiation Dosimetry and Measurement
Cloutier, R. J. (1989) · Radiation Research · doi:10.2307/3577533 · Cited by 1,076
THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS
Wambersie, A. (2004) · Journal of the ICRU · doi:10.1093/jicru/ndh019 · Cited by 869
Even‐Sapir, E., Metser, U., Mishani, E., Lievshitz, G., Lerman, H., & Leibovitch, I. (2006) · PubMed · Cited by 795
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Skeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A., & Treves, S. T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 520
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Möller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.012 · Cited by 455
(2008) · Annals of the ICRP · doi:10.1016/j.icrp.2008.08.003 · Cited by 390
Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human Tissues
Kinoshita, Y., Kuratsukuri, K., Landas, S., Imaida, K., Rovito, P. M., Wang, C. Y., & Haas, G. P. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0544-5 · Cited by 380
Evans, M. J., Smith-Jones, P. M., Wongvipat, J., Navarro, V., Kim, S., Bander, N. H., Larson, S. M., & Sawyers, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106383108 · Cited by 316
PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT
Stabin, M. G., & Siegel, J. A. (2003) · Health Physics · doi:10.1097/00004032-200309000-00006 · Cited by 313
Schuster, D. M., Votaw, J. R., Nieh, P. T., Yu, W., Nye, J. A., Master, V. A., Bowman, F. D., Issa, M. M., & Goodman, M. M. (2007) · PubMed · Cited by 275
Mease, R. C., Dusich, C. L., Foss, C. A., Ravert, H. T., Dannals, R. F., Seidel, J., Prideaux, A., Fox, J. J., Sgouros, G., Kozikowski, A. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1517 · Cited by 223
Self-citationColumn-switching HPLC for the analysis of plasma in PET imaging studies
Hilton, J., Yokoi, F., Dannals, R. F., Ravert, H. T., Szabo, Z., & Wong, D. F. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00125-6 · Cited by 222
Self-citationChallenges in Clinical Prostate Cancer: Role of Imaging
Kelloff, G. J., Choyke, P., & Coffey, D. S. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.2579 · Cited by 184
the NCI PRO-CTCAE Study Group, Hay, J. L., Atkinson, T. M., Reeve, B. B., Mitchell, S. A., Mendoza, T. R., Willis, G., Minasian, L. M., Clauser, S. B., Denicoff, A., et al. (2014) · Quality of Life Research · doi:10.1007/s11136-013-0470-1 · Cited by 165
New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
Beltran, H., Beer, T. M., Carducci, M. A., de Bono, J., Gleave, M., Hussain, M., Kelly, W. K., Saad, F., Sternberg, C., Tagawa, S. T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.04.038 · Cited by 163
Self-citation18F-fluorocholine for prostate cancer imaging: a systematic review of the literature
Bauman, G. S., Belhocine, T., Kovacs, M. S., Ward, A. D., Beheshti, M., & Rachinsky, I. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.35 · Cited by 148
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J. R., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., & Bander, N. H. (2010) · Cancer · doi:10.1002/cncr.24795 · Cited by 144
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen
Chang, S. S., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (2001) · Urology · doi:10.1016/s0090-4295(00)01094-3 · Cited by 133
Dose to the Fetus from Radionuclides in the Bladder
Cloutier, R. J., Smith, S. A., Watson, E. E., Snyder, W. S., & Warner, G. G. (1973) · Health Physics · doi:10.1097/00004032-197308000-00009 · Cited by 124
Fundamentals of Nuclear Medicine Dosimetry
Stabin, M. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-74579-4 · Cited by 120
Morris, M. J., Akhurst, T., Larson, S. M., Ditullio, M., Chu, E., Siedlecki, K. L., Verbel, D., Heller, G., Kelly, W. K., Slovin, S. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2034 · Cited by 118
Elsässer‐Beile, U., Reischl, G., Wiehr, S., Bühler, P., Wolf, P., Alt, K., Shively, J. E., Judenhofer, M. S., Machulla, H. ‐., & Pichler, B. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058487 · Cited by 89
Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II
Bařinka, C., Rovenská, M., Mlčochová, P., Hlouchová, K., Plechanovová, A., Majer, P., Tsukamoto, T., Slusher, B. S., Konvalinka, J., & Lubkowski, J. T. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070133w · Cited by 87
Self-citationHillier, S., Kern, A. M., Maresca, K. P., Marquis, J. C., Eckelman, W. C., Joyal, J. L., & Babich, J. W. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086751 · Cited by 84
Foss, C. A., Mease, R. C., Cho, S. Y., Kim, H. J., & Pomper, M. G. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799462612 · Cited by 79
Self-citationWILKINSON, S., & Chodak, G. W. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000132138.02846.08 · Cited by 73
Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease
Walczak, J., & Carducci, M. A. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.2.243 · Cited by 71
Self-citationKinetics and inhibition of glutamate carboxypeptidase II using a microplate assay
Rojas, C. J., Frazier, S. T., Flanary, J. M., et al. (2002) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00286-5 · Cited by 63
Self-citation
Cited by
Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Hadaschik, B. A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 915
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Giesel, F. L., Hadaschik, B., Cardinale, J., Radtke, J., Vinsensia, M., Lehnert, W., Kesch, C., Tolstov, Y., Singer, S., Grabe, N., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 592
Weineisen, M., Schottelius, M., Simecek, J., Baum, R. P., Yildiz, A., Beykan, S., Kulkarni, H. R., Lassmann, M., Klette, I., Eiber, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 532
Metadata
- Authors
- Cho, S. Y., Gage, K. L., Mease, R. C., Senthamizhchelvan, S., Holt, D. P., Jeffrey-Kwanisai, A., Endres, C. J., Dannals, R. F., Sgouros, G., Lodge, M., Eisenberger, M. A., Rodriguez, R., Carducci, M. A., Rojas, C., Slusher, B. S., Kozikowski, A. P., & Pomper, M. G.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-11-30
- Volume
- 53
- Issue
- 12
- Pages
- 1883-1891
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W1998345392
- Cited by
- 279
- References
- 32
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.